{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:02:22Z","timestamp":1789650142254,"version":"4.0.0"},"reference-count":246,"publisher":"Impact Journals, LLC","issue":"60","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,24]]},"DOI":"10.18632\/oncotarget.18309","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T15:50:16Z","timestamp":1496245816000},"page":"102617-102639","source":"Crossref","is-referenced-by-count":122,"title":["Review: Oncolytic virotherapy, updates and future directions"],"prefix":"10.18632","volume":"8","author":[{"given":"Christos","family":"Fountzilas","sequence":"first","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukeshi","family":"Patel","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devalingam","family":"Mahalingam","sequence":"additional","affiliation":[{"name":"The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,31]]},"reference":[{"issue":"Suppl 1","key":"1","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1007\/s00005-008-0047-9","article-title":"Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers","volume":"56","author":"Horvath","year":"2008","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2","first-page":"473","article-title":"Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report","volume":"9","author":"Von Haam","year":"1949","journal-title":"Cancer Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Coen","year":"1991","journal-title":"Science"},{"key":"4","unstructured":"FDA. 2015. \u201cFDA approves first-of-its-kind product for the treatment of melanoma.\u201d. Retrieved April 12th, 2016 Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm469571.htm."},{"key":"5","unstructured":"EMA. 2015. \u201cFirst oncolytic immunotherapy medicine recommended for approval.\u201d. Retrieved July 28th, 2016. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2015\/10\/news_detail_002421.jsp&mid=WC0b01ac058004d5c1."},{"key":"6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/sj.mt.6300207","article-title":"Proteolytic disassembly is a critical determinant for reovirus oncolysis","volume":"15","author":"Forsyth","year":"2007","journal-title":"Mol Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/sj.mt.6300179","article-title":"Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release","volume":"15","author":"Lee","year":"2007","journal-title":"Mol Ther"},{"key":"8","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Lee","year":"1998","journal-title":"EMBO J"},{"key":"9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S0022172400025109","article-title":"The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice","volume":"81","author":"Wildy","year":"1978","journal-title":"J Hyg (Lond)"},{"key":"10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1099\/0022-1317-24-3-465","article-title":"Induction of both thymidine and deoxycytidine kinase activity by herpes viruses","volume":"24","author":"Subak-Sharpe","year":"1974","journal-title":"J Gen Virol"},{"key":"11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Roizman","year":"2001","journal-title":"Lancet"},{"key":"12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ejcb.2009.06.005","article-title":"Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays","volume":"88","author":"Eriksson","year":"2009","journal-title":"Eur J Cell Biol"},{"key":"13","doi-asserted-by":"publisher","first-page":"798526","DOI":"10.1155\/2012\/798526","article-title":"Retargeting of viruses to generate oncolytic agents","author":"Rottier","year":"2012","journal-title":"Adv Virol"},{"key":"14","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1158\/1078-0432.CCR-08-0831","article-title":"Tumor infection by oncolytic reovirus primes adaptive antitumor immunity","volume":"14","author":"Melcher","year":"2008","journal-title":"Clin Cancer Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/10430349950018832","article-title":"Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity","volume":"10","author":"Martuza","year":"1999","journal-title":"Hum Gene Ther"},{"key":"16","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","article-title":"In situ cancer vaccination: an IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor activity","volume":"160","author":"Rabkin","year":"1998","journal-title":"J Immunol"},{"key":"17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/gt.2008.42","article-title":"Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery","volume":"15","author":"Contag","year":"2008","journal-title":"Gene Ther"},{"key":"18","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Hemminki","year":"2012","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/0008-5472.CAN-11-3185","article-title":"Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma","volume":"72","author":"Tani","year":"2012","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/gt.2011.205","article-title":"Measles virus causes immunogenic cell death in human melanoma","volume":"20","author":"Russell","year":"2013","journal-title":"Gene Ther"},{"key":"21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kroemer","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/mt.2011.26","article-title":"Targeting tumor vasculature with an oncolytic virus","volume":"19","author":"Lichty","year":"2011","journal-title":"Mol Ther"},{"key":"23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1089\/hum.2005.16.765","article-title":"Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma","volume":"16","author":"Coukos","year":"2005","journal-title":"Hum Gene Ther"},{"key":"24","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Chen","year":"2013","journal-title":"Cancer Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ymthe.2004.12.015","article-title":"Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1","volume":"11","author":"Liu","year":"2005","journal-title":"Mol Ther"},{"key":"26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10549-014-3180-7","article-title":"A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer","volume":"156","author":"Fong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"27","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/ijc.28747","article-title":"Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF","volume":"135","author":"Thorne","year":"2014","journal-title":"Int J Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"26319","DOI":"10.1074\/jbc.M111.253443","article-title":"Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity","volume":"286","author":"Silverman","year":"2011","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/mt.2013.112","article-title":"Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy","volume":"21","author":"Silverman","year":"2013","journal-title":"Mol Ther"},{"key":"30","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1099\/0022-1317-81-11-2605","article-title":"Blood clearance rates of adenovirus type 5 in mice","volume":"81","author":"Curiel","year":"2000","journal-title":"J Gen Virol"},{"key":"31","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","article-title":"A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor","volume":"12","author":"Nutting","year":"2006","journal-title":"Clin Cancer Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Curti","year":"2015","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Love","year":"2009","journal-title":"J Clin Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy","volume":"6","author":"Allison","year":"2014","journal-title":"Sci Transl Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-642-77247-4_7","article-title":"The role of herpes simplex virus glycoproteins in immune evasion","volume":"179","author":"Friedman","year":"1992","journal-title":"Curr Top Microbiol Immunol"},{"key":"36","first-page":"2297","volume-title":"Fields Virology","author":"Straus","year":"1996"},{"key":"37","first-page":"1307","volume-title":"Reoviruses","author":"Roizman","year":"1990","edition":"2nd"},{"key":"38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.gt.3302038","article-title":"Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells","volume":"10","author":"Chiocca","year":"2003","journal-title":"Gene Ther"},{"key":"39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/mthe.2000.0130","article-title":"Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor","volume":"2","author":"Rabkin","year":"2000","journal-title":"Mol Ther"},{"key":"40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/JVI.68.1.48-55.1994","article-title":"ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures","volume":"68","author":"Thompson","year":"1994","journal-title":"J Virol"},{"key":"41","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1099\/0022-1317-75-12-3679","article-title":"ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro","volume":"75","author":"Harland","year":"1994","journal-title":"J Gen Virol"},{"key":"42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1073\/pnas.94.3.843","article-title":"The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase","volume":"94","author":"Roizman","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"43","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.2173860","article-title":"Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture","volume":"250","author":"Roizman","year":"1990","journal-title":"Science"},{"key":"44","doi-asserted-by":"publisher","first-page":"10516","DOI":"10.1073\/pnas.92.23.10516","article-title":"Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1","volume":"92","author":"Roizman","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/JVI.70.1.84-90.1996","article-title":"The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells","volume":"70","author":"Roizman","year":"1996","journal-title":"J Virol"},{"key":"46","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.onc.1208420","article-title":"Potential molecular mechanism for rodent tumorigenesis: mutational generation of Progression Elevated Gene-3 (PEG-3)","volume":"24","author":"Fisher","year":"2005","journal-title":"Oncogene"},{"key":"47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/bjc.1996.431","article-title":"Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours\u2014evaluation of a potentially effective clinical therapy","volume":"74","author":"Brown","year":"1996","journal-title":"Br J Cancer"},{"key":"48","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1099\/0022-1317-72-3-631","article-title":"Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the \u2018a\u2019 sequence","volume":"72","author":"Brown","year":"1991","journal-title":"J Gen Virol"},{"key":"49","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/JVI.73.4.3375-3385.1999","article-title":"A herpesvirus ribosome-associated, RNA-binding protein confers a growth advantage upon mutants deficient in a GADD34-related function","volume":"73","author":"Mohr","year":"1999","journal-title":"J Virol"},{"key":"50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/375415a0","article-title":"A viral inhibitor of peptide transporters for antigen presentation","volume":"375","author":"Yang","year":"1995","journal-title":"Nature"},{"key":"51","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0092-8674(94)90215-1","article-title":"A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes","volume":"77","author":"Johnson","year":"1994","journal-title":"Cell"},{"key":"52","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Hodi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"54","first-page":"9029","article-title":"Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma","volume":"32","author":"Kaufman","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"55","first-page":"9063","article-title":"Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma","volume":"33","author":"Kaufman","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"56","doi-asserted-by":"publisher","first-page":"S722","DOI":"10.1016\/S0959-8049(16)31944-X","article-title":"24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma","volume":"51","author":"Kirkwood","year":"2015","journal-title":"Eur J Cancer"},{"key":"57","first-page":"TPS9081","article-title":"A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma","volume":"33","author":"Chou","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"58","first-page":"9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Gajewski","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/(SICI)1099-1654(199707)7:2<107::AID-RMV191>3.0.CO;2-M","article-title":"Capsid assembly and DNA packaging in herpes simplex virus","volume":"7","author":"Brown","year":"1997","journal-title":"Rev Med Virol"},{"key":"60","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbamcr.2010.03.007","article-title":"Herpesviruses: hijacking the Ras signaling pathway","author":"Sourvinos","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"61","first-page":"S1","article-title":"Herpes simplex virus virulence: the functions of the gamma (1)34.5 gene","volume":"3","author":"Markovitz","year":"1997","journal-title":"J Neurovirol"},{"key":"62","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Martuza","year":"1995","journal-title":"Nat Med"},{"key":"63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0042-6822(88)90144-4","article-title":"Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant","volume":"166","author":"Weller","year":"1988","journal-title":"Virology"},{"key":"64","first-page":"3963","article-title":"Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant","volume":"54","author":"Martuza","year":"1994","journal-title":"Cancer Res"},{"key":"65","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/sj.cgt.7700537","article-title":"Oncolytic herpes simplex virus vectors for cancer virotherapy","volume":"9","author":"Rabkin","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"66","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1074\/jbc.273.3.1435","article-title":"The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase","volume":"273","author":"Massie","year":"1998","journal-title":"J Biol Chem"},{"key":"67","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Martuza","year":"2000","journal-title":"Gene Ther"},{"key":"68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","article-title":"Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM","volume":"17","author":"Gillespie","year":"2009","journal-title":"Mol Ther"},{"key":"69","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","article-title":"A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses","volume":"22","author":"Parker","year":"2014","journal-title":"Mol Ther"},{"key":"70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF01379108","article-title":"Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice","volume":"134","author":"Becker","year":"1994","journal-title":"Arch Virol"},{"key":"71","doi-asserted-by":"publisher","first-page":"11307","DOI":"10.1073\/pnas.93.21.11307","article-title":"The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors","volume":"93","author":"Roizman","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"72","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","article-title":"Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver","volume":"17","author":"Kowal","year":"2006","journal-title":"Hum Gene Ther"},{"key":"73","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/mt.2008.240","article-title":"A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer","volume":"17","author":"Kemeny","year":"2009","journal-title":"Mol Ther"},{"key":"74","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/00016480600702100","article-title":"Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma","volume":"126","author":"Nishiyama","year":"2006","journal-title":"Acta Otolaryngol"},{"key":"75","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1245\/ASO.2006.08.035","article-title":"Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer","volume":"13","author":"Nakao","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/cgt.2010.65","article-title":"A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer","volume":"18","author":"Takeda","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"77","first-page":"6082","article-title":"Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+\/HSV- patients with refractory and superficial cancers","volume":"32","author":"Nishiyama","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","article-title":"Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma","volume":"6","author":"Lattime","year":"1999","journal-title":"Cancer Gene Ther"},{"key":"79","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1470-2045(08)70107-4","article-title":"Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial","volume":"9","author":"Park","year":"2008","journal-title":"Lancet Oncol"},{"key":"80","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/mt.2011.132","article-title":"A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma","volume":"19","author":"Kirn","year":"2011","journal-title":"Mol Ther"},{"key":"81","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/mt.2011.39","article-title":"Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy","volume":"19","author":"Hickman","year":"2011","journal-title":"Mol Ther"},{"key":"82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejrad.2015.10.024","article-title":"CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1","volume":"85","author":"Laurent","year":"2016","journal-title":"Eur J Radiol"},{"key":"83","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Benjamin","year":"2007","journal-title":"J Clin Oncol"},{"key":"84","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Hickman","year":"2013","journal-title":"Nat Med"},{"key":"85","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Burns","year":"2011","journal-title":"Nature"},{"key":"86","first-page":"3608","article-title":"Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)","volume":"31","author":"Kirn","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"87","first-page":"TPS4161","article-title":"Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)","volume":"31","author":"Hickman","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"88","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.cgt.7700431","article-title":"Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma","volume":"9","author":"Jensen","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"89","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"key":"90","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/sj.gt.3301319","article-title":"Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status","volume":"7","author":"Kirn","year":"2000","journal-title":"Gene Ther"},{"key":"91","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","article-title":"Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells","volume":"72","author":"zur Hausen","year":"1998","journal-title":"J Virol"},{"key":"92","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/78638","article-title":"a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Bruso","year":"2000","journal-title":"Nat Med"},{"key":"93","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"94","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.CCR-05-1059","article-title":"CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor\u2014armed oncolytic adenovirus for the treatment of bladder cancer","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"95","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-1-4615-1809-9_7","article-title":"Cell cycle-regulated transcription in mammalian cells","volume":"1","author":"M\u00fcller","year":"1995","journal-title":"Prog Cell Cycle Res"},{"key":"96","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"McKiernan","year":"2012","journal-title":"J Urol"},{"key":"97","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1046\/j.1439-0450.2000.00411.x","article-title":"Apoptosis in feline panleukopenia and canine parvovirus enteritis","volume":"47","author":"Weissenb\u00f6ck","year":"2000","journal-title":"J Vet Med B Infect Dis Vet Public Health"},{"key":"98","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1128\/JVI.62.8.2884-2889.1988","article-title":"The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells","volume":"62","author":"Young","year":"1988","journal-title":"J Virol"},{"key":"99","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1128\/JVI.72.11.8893-8903.1998","article-title":"Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway","volume":"72","author":"Dinsart","year":"1998","journal-title":"J Virol"},{"key":"100","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/path.1711690207","article-title":"Ultrastructural features of fetal erythroid precursors infected with parvovirus B19 in vitro: evidence of cell death by apoptosis","volume":"169","author":"Fleming","year":"1993","journal-title":"J Pathol"},{"key":"101","doi-asserted-by":"publisher","first-page":"8702","DOI":"10.1073\/pnas.90.18.8702","article-title":"A model for tumor suppression using H-1 parvovirus","volume":"90","author":"Amson","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"102","first-page":"5s","article-title":"First combined intravenous and intracerebral application of an oncolytic virus, parvoviras h-1, in a phase I\/IIa clinical trial in patients with recurrent glioblastoma multiforme (ParvOryx01)","volume":"32","author":"Unterberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"103","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/neuonc\/nou255.21","article-title":"Combination of intravenous and intracerebral injection of oncolytic parvovirus H-1 in a phase I\/IIA clinical trial of patients with recurrent glioblastoma multiforme: penetration of H-1 virus across the blood-brain barrier","volume":"16","author":"Rommelaere","year":"2014","journal-title":"Neuro-oncol"},{"key":"104","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fonc.2014.00167","article-title":"Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells","volume":"4","author":"Mita","year":"2014","journal-title":"Front Oncol"},{"key":"105","doi-asserted-by":"publisher","first-page":"11099","DOI":"10.1073\/pnas.0404310101","article-title":"Reovirus oncolysis: the Ras\/RalGEF\/p38 pathway dictates host cell permissiveness to reovirus infection","volume":"101","author":"Lee","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"106","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/bjc.2011.325","article-title":"Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-\u03baB activation","volume":"105","author":"Lee","year":"2011","journal-title":"Br J Cancer"},{"key":"107","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1359-6349(06)70335-4","article-title":"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents against non-small cell lung cancer","volume":"4","author":"Tomaszewski","year":"2006","journal-title":"Eur J Cancer, Suppl"},{"key":"108","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/ijc.27918","article-title":"Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells","volume":"132","author":"Melcher","year":"2013","journal-title":"Int J Cancer"},{"key":"109","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fonc.2014.00077","article-title":"Oncolytic virus-mediated reversal of impaired tumor antigen presentation","volume":"4","author":"Lee","year":"2014","journal-title":"Front Oncol"},{"key":"110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/biores.2012.0205","article-title":"Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia","volume":"1","author":"Melcher","year":"2012","journal-title":"Biores Open Access"},{"key":"111","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1359-6349(04)80460-9","article-title":"The oncolytic reovirus, REOLYSIN\u00ae, augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116","volume":"2","author":"Coffey","year":"2004","journal-title":"Eur J Cancer"},{"key":"112","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.canlet.2014.10.046","article-title":"Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells","volume":"356","author":"Joh","year":"2015","journal-title":"Cancer Lett"},{"key":"113","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1158\/1078-0432.CCR-09-0796","article-title":"Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"114","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1476-4598-8-47","article-title":"Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells","volume":"8","author":"Tomaszewski","year":"2009","journal-title":"Mol Cancer"},{"key":"115","first-page":"348","article-title":"Systemic reovirus therapy of metastatic cancer in immune-competent mice","volume":"63","author":"Lee","year":"2003","journal-title":"Cancer Res"},{"key":"116","first-page":"1218","article-title":"Oncolytic viral therapy for human pancreatic cancer cells by reovirus","volume":"9","author":"Kitano","year":"2003","journal-title":"Clin Cancer Res"},{"key":"117","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1038\/cddis.2013.259","article-title":"Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer","volume":"4","author":"Nawrocki","year":"2013","journal-title":"Cell Death Dis"},{"key":"118","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3892\/or_00000364","article-title":"Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model","volume":"21","author":"Kitano","year":"2009","journal-title":"Oncol Rep"},{"key":"119","first-page":"901","article-title":"Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models","volume":"27","author":"Kitano","year":"2005","journal-title":"Int J Oncol"},{"key":"120","volume-title":"AACR 108th Annual Meeting","author":"Seymour","year":"2017"},{"key":"121","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/cncr.29856","article-title":"Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors","volume":"122","author":"Knopp","year":"2016","journal-title":"Cancer"},{"key":"122","doi-asserted-by":"publisher","first-page":"iv51","DOI":"10.1093\/annonc\/mdv233.175","article-title":"Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma","volume":"26","author":"Mita","year":"2015","journal-title":"Ann Oncol"},{"key":"123","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12885-015-1518-0","article-title":"The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer","volume":"15","author":"Nawrocki","year":"2015","journal-title":"BMC Cancer"},{"key":"124","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/annonc\/mdu438.19","article-title":"LBA19A multi-institutional randomized phase 2 trial of the oncolytic virus reolysin in the first line treatment metastatic adenocarcinoma of the pancreas (MAP)","author":"Wu","year":"2014","journal-title":"Ann Oncol"},{"key":"125","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Mace","year":"2016","journal-title":"Mol Ther"},{"key":"126","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1158\/1078-0432.CCR-10-0054","article-title":"Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers","volume":"16","author":"Coffey","year":"2010","journal-title":"Clin Cancer Res"},{"key":"127","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1172\/JCI113426","article-title":"Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro","volume":"81","author":"Medof","year":"1988","journal-title":"J Clin Invest"},{"key":"128","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1054\/bjoc.2000.1570","article-title":"CD55 is over-expressed in the tumour environment","volume":"84","author":"Durrant","year":"2001","journal-title":"Br J Cancer"},{"key":"129","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/JVI.71.6.4736-4743.1997","article-title":"Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry","volume":"71","author":"Barry","year":"1997","journal-title":"J Virol"},{"key":"130","first-page":"1471","article-title":"Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21","volume":"26","author":"Shafren","year":"2005","journal-title":"Int J Oncol"},{"key":"131","first-page":"9030","article-title":"Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma","volume":"33","author":"Weisberg","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"132","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/35022579","article-title":"SLAM (CDw150) is a cellular receptor for measles virus","volume":"406","author":"Yanagi","year":"2000","journal-title":"Nature"},{"key":"133","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1128\/JVI.67.10.6025-6032.1993","article-title":"Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus","volume":"67","author":"Gerlier","year":"1993","journal-title":"J Virol"},{"key":"134","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","article-title":"The human CD46 molecule is a receptor for measles virus (Edmonston strain)","volume":"75","author":"Richardson","year":"1993","journal-title":"Cell"},{"key":"135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2222\/jsv.51.201","article-title":"[The cellular receptor for measles virus]","volume":"51","author":"Yanagi","year":"2001","journal-title":"[Article in Japanese]. Uirusu"},{"key":"136","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0161-5890(03)00112-3","article-title":"Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors","volume":"40","author":"Kirschfink","year":"2003","journal-title":"Mol Immunol"},{"key":"137","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1158\/0008-5472.CAN-04-0884","article-title":"High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus","volume":"64","author":"Peng","year":"2004","journal-title":"Cancer Res"},{"key":"138","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1099\/0022-1317-72-2-439","article-title":"Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion","volume":"72","author":"Buckland","year":"1991","journal-title":"J Gen Virol"},{"key":"139","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1089\/104303401750148766","article-title":"Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas","volume":"12","author":"Russell","year":"2001","journal-title":"Hum Gene Ther"},{"key":"140","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Fielding","year":"2001","journal-title":"Blood"},{"key":"141","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model","volume":"122","author":"Galanis","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"142","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/hep.21437","article-title":"Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma","volume":"44","author":"LaRusso","year":"2006","journal-title":"Hepatology"},{"key":"143","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","article-title":"Systemic therapy of myeloma xenografts by an attenuated measles virus","volume":"98","author":"Russell","year":"2001","journal-title":"Blood"},{"key":"144","first-page":"4656","article-title":"Intraperitoneal therapy of ovarian cancer using an engineered measles virus","volume":"62","author":"Russell","year":"2002","journal-title":"Cancer Res"},{"key":"145","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/1471-2407-12-427","article-title":"Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma","volume":"12","author":"Yuan","year":"2012","journal-title":"BMC Cancer"},{"key":"146","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Atherton","year":"2010","journal-title":"Cancer Res"},{"key":"147","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Federspiel","year":"2015","journal-title":"Cancer Res"},{"key":"148","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Gertz","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"149","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","article-title":"Newcastle disease virus selectively kills human tumor cells","volume":"52","author":"Greager","year":"1992","journal-title":"J Surg Res"},{"key":"150","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/jnci\/86.16.1228","article-title":"Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy","volume":"86","author":"Peeples","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"151","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1128\/JVI.77.17.9522-9532.2003","article-title":"Newcastle disease virus V protein is a determinant of host range restriction","volume":"77","author":"Palese","year":"2003","journal-title":"J Virol"},{"key":"152","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-61779-340-0_13","article-title":"Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation","volume":"797","author":"Schirrmacher","year":"2012","journal-title":"Methods Mol Biol"},{"key":"153","first-page":"618","article-title":"Overview of phase I studies of intravenous administration of PV701, an oncolytic virus","volume":"5","author":"Bamat","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"154","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","article-title":"Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers","volume":"20","author":"Lorence","year":"2002","journal-title":"J Clin Oncol"},{"key":"155","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/B","article-title":"MTH-68\/H oncolytic viral treatment in human high-grade gliomas","volume":"67","author":"Csatary","year":"2004","journal-title":"J Neurooncol"},{"key":"156","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1128\/JVI.00401-09","article-title":"The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin","volume":"84","author":"Ben-Yehuda","year":"2010","journal-title":"J Virol"},{"key":"157","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Siegal","year":"2006","journal-title":"Mol Ther"},{"key":"158","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.str.2008.07.013","article-title":"Structure of Seneca Valley Virus-001: an oncolytic picornavirus representing a new genus","volume":"16","author":"Reddy","year":"2008","journal-title":"Structure"},{"key":"159","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1099\/vir.0.83570-0","article-title":"Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus","volume":"89","author":"Hallenbeck","year":"2008","journal-title":"J Gen Virol"},{"key":"160","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S1744309108006921","article-title":"Crystallization and preliminary X-ray diffraction studies of Seneca Valley virus-001, a new member of the Picornaviridae family","volume":"64","author":"Reddy","year":"2008","journal-title":"Acta Crystallogr Sect F Struct Biol Cryst Commun"},{"key":"161","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/jnci\/djm198","article-title":"Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers","volume":"99","author":"Hallenbeck","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"162","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-10-1706","article-title":"Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features","volume":"17","author":"Hallenbeck","year":"2011","journal-title":"Clin Cancer Res"},{"key":"163","doi-asserted-by":"publisher","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Barber","year":"2003","journal-title":"J Virol"},{"key":"164","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/hum.2009.088","article-title":"Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy","volume":"21","author":"Russell","year":"2010","journal-title":"Hum Gene Ther"},{"key":"165","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1097-2765(00)00120-9","article-title":"Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98","volume":"6","author":"Izaurralde","year":"2000","journal-title":"Mol Cell"},{"key":"166","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/hum.2007.163","article-title":"rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy","volume":"19","author":"Woo","year":"2008","journal-title":"Hum Gene Ther"},{"key":"167","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1089\/hum.2009.111","article-title":"Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates","volume":"21","author":"Meier","year":"2010","journal-title":"Hum Gene Ther"},{"key":"168","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-07-1510","article-title":"Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus","volume":"14","author":"Harrington","year":"2008","journal-title":"Clin Cancer Res"},{"key":"169","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/pbc.25464","article-title":"A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report","volume":"62","author":"Blaney","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"170","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/bjc.2013.695","article-title":"Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms","volume":"110","author":"Lee","year":"2014","journal-title":"Br J Cancer"},{"key":"171","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1158\/1078-0432.CCR-10-2159","article-title":"A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer","volume":"17","author":"de Bono","year":"2011","journal-title":"Clin Cancer Res"},{"key":"172","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Wahle","year":"2016","journal-title":"J Immunother Cancer"},{"key":"173","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Sharpe","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"174","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses","volume":"24","author":"Vile","year":"2016","journal-title":"Mol Ther"},{"key":"175","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses","volume":"23","author":"K\u00fchnel","year":"2015","journal-title":"Mol Ther"},{"key":"176","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Peng","year":"2016","journal-title":"Blood"},{"key":"177","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/neuonc\/nov173","article-title":"Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling","volume":"18","author":"Vile","year":"2016","journal-title":"Neuro-oncol"},{"key":"178","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Ungerechts","year":"2014","journal-title":"Mol Ther"},{"issue":"Suppl 3","key":"179","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/2051-1426-2-S3-P112","article-title":"Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation","volume":"2","author":"Rajesekaran","year":"2014","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"180","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Ahmed","year":"2006","journal-title":"Nature"},{"key":"181","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/1538-7445.AM2015-5355","article-title":"Abstract 5355: Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer","volume":"75","author":"Morris","year":"2015","journal-title":"Cancer Res"},{"key":"182","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/mt.2015.15","article-title":"BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress","volume":"23","author":"Melcher","year":"2015","journal-title":"Mol Ther"},{"key":"183","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Andtbacka","year":"2016","journal-title":"J Clin Oncol"},{"key":"184","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells","volume":"194","author":"Ha","year":"2015","journal-title":"J Immunol"},{"key":"185","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","article-title":"Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant","volume":"7","author":"Bartlett","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"186","doi-asserted-by":"crossref","first-page":"13836","DOI":"10.1016\/S0021-9258(17)36723-6","article-title":"Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells","volume":"269","author":"Wawra","year":"1994","journal-title":"J Biol Chem"},{"key":"187","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0042-6822(88)90635-6","article-title":"Cell proliferative response to vaccinia virus is mediated by VGF","volume":"164","author":"Fredrickson","year":"1988","journal-title":"Virology"},{"key":"188","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity","volume":"23","author":"Hu","year":"2015","journal-title":"Mol Ther"},{"key":"189","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Hwang","year":"2006","journal-title":"Mol Ther"},{"key":"190","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-07-0146","article-title":"Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus","volume":"67","author":"Szalay","year":"2007","journal-title":"Cancer Res"},{"key":"191","first-page":"7559","article-title":"Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion","volume":"33","author":"Rusch","year":"2015","journal-title":"ASCO Meeting Abstracts"},{"key":"192","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1200\/jco.2013.31.15_suppl.3098","article-title":"Phase I\/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresactable, chemotherapy-resistant peritoneal carcinomatosis","volume":"31","author":"Yu","year":"2013","journal-title":"J Clin Oncol"},{"key":"193","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/jco.2012.30.15_suppl.2530","article-title":"Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging","volume":"30","author":"De Bono","year":"2012","journal-title":"J Clin Oncol"},{"key":"194","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/jco.2013.31.15_suppl.3062","article-title":"Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging (NCT009794131)","volume":"31","author":"De Bono","year":"2013","journal-title":"J Clin Oncol"},{"key":"195","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Kyritsis","year":"2000","journal-title":"Oncogene"},{"key":"196","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Alvarez","year":"2013","journal-title":"Gynecol Oncol"},{"key":"197","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Haavisto","year":"2012","journal-title":"Int J Cancer"},{"key":"198","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Rouvinen-Lagerstr\u00f6m","year":"2014","journal-title":"Int J Cancer"},{"key":"199","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/neuonc\/nou265.17","article-title":"Phase I clinical trial of oncolytic virus delta-24-rgd (DNX-2401) with biological endpoints: implications for viro-immunotherapy","author":"Fueyo","year":"2014","journal-title":"Neuro-oncol"},{"key":"200","doi-asserted-by":"publisher","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5","volume":"78","author":"Zuijdgeest","year":"2004","journal-title":"J Virol"},{"key":"201","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Hermiston","year":"2008","journal-title":"PLoS One"},{"key":"202","first-page":"TPS3112","article-title":"A phase 1 mechanism of action study of intratumoral or intravenous administration of enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumor","volume":"32","author":"Jurado","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"203","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Henderson","year":"1997","journal-title":"Cancer Res"},{"key":"204","first-page":"1498","article-title":"Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy","volume":"59","author":"Henderson","year":"1999","journal-title":"Cancer Res"},{"key":"205","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1586\/era.10.200","article-title":"Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer","volume":"11","author":"Kagawa","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"206","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/SLA.0b013e3181deb69d","article-title":"In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy","volume":"251","author":"Urata","year":"2010","journal-title":"Ann Surg"},{"key":"207","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1089\/hum.2005.16.996","article-title":"Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells","volume":"16","author":"Heike","year":"2005","journal-title":"Hum Gene Ther"},{"key":"208","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/neuonc\/noq023","article-title":"Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models","volume":"12","author":"Schlehofer","year":"2010","journal-title":"Neuro-oncol"},{"key":"209","first-page":"1493","article-title":"Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model","volume":"17","author":"Rommelaere","year":"2007","journal-title":"Oncol Rep"},{"key":"210","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/030794500750047126","article-title":"Circoviruses: immunosuppressive threats to avian species: a review","volume":"29","author":"Todd","year":"2000","journal-title":"Avian Pathol"},{"key":"211","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.vetmic.2003.10.003","article-title":"Chicken anemia virus induced apoptosis: underlying molecular mechanisms","volume":"98","author":"Noteborn","year":"2004","journal-title":"Vet Microbiol"},{"key":"212","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/sj.cdd.4401391","article-title":"Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing","volume":"11","author":"Noteborn","year":"2004","journal-title":"Cell Death Differ"},{"key":"213","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1242\/jcs.02580","article-title":"Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway","volume":"118","author":"Los","year":"2005","journal-title":"J Cell Sci"},{"key":"214","first-page":"486","article-title":"Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells","volume":"55","author":"Noteborn","year":"1995","journal-title":"Cancer Res"},{"key":"215","first-page":"666","article-title":"Potential prognostic tumor biomarkers in triple-negative breast carcinoma","volume":"44","author":"Peng","year":"2012","journal-title":"Beijing Da Xue Xue Bao"},{"key":"216","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1742-7843.2006.00016.x","article-title":"Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells","volume":"100","author":"Noteborn","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"217","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1099\/vir.0.82085-0","article-title":"Anti-neoplastic effect of chicken anemia virus VP3 protein (apoptin) in Rous sarcoma virus-induced tumours in chicken","volume":"87","author":"Sylvester","year":"2006","journal-title":"J Gen Virol"},{"key":"218","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1128\/JVI.74.7.2981-2989.2000","article-title":"Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB","volume":"74","author":"Dermody","year":"2000","journal-title":"J Virol"},{"key":"219","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1128\/JVI.78.23.13132-13138.2004","article-title":"JNK regulates the release of proapoptotic mitochondrial factors in reovirus-infected cells","volume":"78","author":"Tyler","year":"2004","journal-title":"J Virol"},{"key":"220","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10637-009-9279-8","article-title":"Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors","volume":"28","author":"Goel","year":"2010","journal-title":"Invest New Drugs"},{"key":"221","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","article-title":"A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer","volume":"14","author":"DeBono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"222","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Hamilton","year":"2008","journal-title":"Mol Ther"},{"key":"223","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10637-012-9865-z","article-title":"REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin\u00ae) in patients with advanced solid tumors","volume":"31","author":"Thompson","year":"2013","journal-title":"Invest New Drugs"},{"key":"224","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Markert","year":"2014","journal-title":"Mol Ther"},{"key":"225","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","article-title":"REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer","volume":"16","author":"Phelps","year":"2010","journal-title":"Clin Cancer Res"},{"key":"226","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-11-2181","article-title":"Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies","volume":"18","author":"Mettinger","year":"2012","journal-title":"Clin Cancer Res"},{"key":"227","first-page":"450","article-title":"A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan\/fluorouracil\/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory\/intolerant KRAS-mutant metastatic colorectal cancer (mCRC)","volume":"31","author":"Hou","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"228","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s10637-010-9614-0","article-title":"Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride","volume":"30","author":"Shafren","year":"2012","journal-title":"Invest New Drugs"},{"key":"229","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/mt.2008.152","article-title":"Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity","volume":"16","author":"Galanis","year":"2008","journal-title":"Mol Ther"},{"key":"230","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nm0502-527","article-title":"Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides","volume":"8","author":"Russell","year":"2002","journal-title":"Nat Med"},{"key":"231","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Russell","year":"2004","journal-title":"Blood"},{"key":"232","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/mt.2009.218","article-title":"Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter","volume":"17","author":"Galanis","year":"2009","journal-title":"Mol Ther"},{"key":"233","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/hum.2008.035","article-title":"Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I\/II clinical trial for patients with recurrent gliomas","volume":"19","author":"Galanis","year":"2008","journal-title":"Hum Gene Ther"},{"key":"234","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"235","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1089\/104303403322495070","article-title":"Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice","volume":"14","author":"Russell","year":"2003","journal-title":"Hum Gene Ther"},{"key":"236","first-page":"677","article-title":"Immunization with virus-modified tumor cells","volume":"25","author":"Steiner","year":"1998","journal-title":"Semin Oncol"},{"key":"237","first-page":"363","article-title":"Newcastle disease virus activates macrophages for anti-tumor activity","volume":"16","author":"Qian","year":"2000","journal-title":"Int J Oncol"},{"key":"238","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.cgt.7700109","article-title":"Newcastle disease virus infection induces B7-1\/B7-2-independent T-cell costimulatory activity in human melanoma cells","volume":"7","author":"Becker","year":"2000","journal-title":"Cancer Gene Ther"},{"key":"239","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0021-9975(96)80083-1","article-title":"Growth of Newcastle disease virus in chicken macrophages","volume":"115","author":"Lam","year":"1996","journal-title":"J Comp Pathol"},{"key":"240","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.virusres.2008.12.008","article-title":"Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis","volume":"141","author":"Chauhan","year":"2009","journal-title":"Virus Res"},{"key":"241","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.virusres.2009.05.012","article-title":"Time course of Newcastle disease virus-induced apoptotic pathways","volume":"144","author":"Chauhan","year":"2009","journal-title":"Virus Res"},{"key":"242","first-page":"2441a","article-title":"PV701, a naturally attenuated strain of Newcastle disease virus, has a broad spectrum of oncolytic activity against human tumor xenografts","volume":"42","author":"Lorence","year":"2001","journal-title":"Proc Am Assoc Cancer Res"},{"key":"243","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1126\/science.1553561","article-title":"Identification of the integrin VLA-2 as a receptor for echovirus 1","volume":"255","author":"Finberg","year":"1992","journal-title":"Science"},{"key":"244","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.20866","article-title":"Oncolysis of human ovarian cancers by echovirus type 1","volume":"115","author":"Barry","year":"2005","journal-title":"Int J Cancer"},{"key":"245","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/pros.20741","article-title":"Potent oncolytic activity of human enteroviruses against human prostate cancer","volume":"68","author":"Shafren","year":"2008","journal-title":"Prostate"},{"key":"246","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Muceniece","year":"2015","journal-title":"Melanoma Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T20:56:01Z","timestamp":1692824161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.18309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,31]]},"references-count":246,"journal-issue":{"issue":"60","published-print":{"date-parts":[[2017,11,24]]}},"alternative-id":["18309","29254276"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.18309","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,31]]}}}